Rutgers Cancer Institute and RWJBarnabas Health announced Monday the appointment of Dr. Andrew Evens as their new oncology leader.
Evens’ area of expertise is primarily in biology, prognosis and treatment of non-Hodgkin lymphoma and Hodgkin lymphoma.
“I look forward to helping enhance the clinical mission of both Rutgers Cancer Institute and RWJBarnabas Health,” Evens said. “By further emphasizing the strengths of our collective advanced clinical offerings and exploring innovative opportunities for improved and additional cancer care services, we will have a valuable impact on oncology outcomes for patients across the region.”
Most recently, Evens served as director of the Cancer Center at Tufts Medical Center in Boston. He is heavily involved with lymphoma research, and has worked as the principal investigator for several national clinical trials, focusing on high-risk follicular lymphoma and newly diagnosed Hodgkin lymphoma. He is also a core member of the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee, and part of the Scientific Advisory Board for the Lymphoma Research Foundation.
In his new position, Evens will facilitate the integration of cancer care across Rutgers and RWJ, including work focused on survivorship, palliative care and navigational support. He also will serve as the director of the Lymphoma Program in the Division of Blood Disorders at Rutgers Cancer Institute, leading a translational lymphoma laboratory that utilizes systems biology analyses and investigates novel targeted therapeutic agents for lymphoma. Evens also has an appointment as a professor of medicine at Rutgers Robert Wood Johnson Medical School.
Rutgers Cancer Institute Director Dr. Steven K. Libutti had only kind words for Evens: “His role in enhancing integrated cancer care, in concert with RWJBarnabas Health, will promote the growth of clinical research and clinical services that will enable us to further address the oncology needs of the state of New Jersey and beyond.”
